IP Library Granted Patent US 7,423,074
Granted Patent B2
US 7,423,074 · App. 11/292,817 · Granted Sep 9, 2008

Polysiloxane prepolymers for biomedical devices

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,423,074
App. No.
11/292,817
Granted
Sep 9, 2008
Kind
B2
Abstract

A polysiloxane copolymer that is useful for forming biomedical devices comprises blocks (I) and (II) and is terminated at each end with an ethylenically unsaturated radical: (*Dii*Diol*Dii*PS) x   (I) (*Dii*PS) y   (II) wherein: each Dii is independently a diradical residue of a diisocyanate; each Diol is independently a diradical residue of a diol having 1 to 10 carbon atoms; each PS is independently a diradical residue of a polysiloxane-containing diol or diamine; each * is independently —NH—CO—NH—, —NH—COO— or —OCO—NH—: x represents the number of blocks (I) and is at least 2, and y represents the number of blocks (II) and is at least 1.

Claims (65)

1. A copolymer that is the polymerization product of a monomeric mixture comprising a copolymer represented by the general formulae,

M(*Dii*Diol*Dii*PS) x (*Dii*PS) y *Dii*M or

M(*Dii*Diol*Dii*PS) x (*Dii*PS) y *Dii*Diol*Dii*M

wherein:

each M is independently a polymerizable ethylenically unsaturated radical;

each Dii is independently a diradical residue of a diisocyanate;

each Diol is independently a diradical residue of a diol having 1 to 10 carbon atoms;

each PS is independently a diradical residue of a polysiloxane-diol or a polysiloxane diamine;

each * is independently —NH—CO—NH—, —NH—COO— or —OCO—NH—;

x is at least 2, and

y is at least 1; and

a hydrophilic comonomer and a monofunctional silicone-containing monomer.

2. The copolymer of claim 1 , wherein each Dii is independently a diradical residue of an aliphatic or an aromatic diisocyanate having 6 to 30 carbon atoms in the aliphatic or aromatic moiety.

3. The copolymer of claim 2 , wherein each Dii is a diradical residue of a diisocyanate selected from the group consisting of isophorone diisocyanate, hexamethylene-1,6-diisocyanate, 4,4′-dicyclohexylmethane diisocyanate, toluene diisocyanate, 4,4′-diphenyl diisocyanate, 4,4′-diphenylmethane diisocyanate, p-phenylene diisocyanate, 1,4-phenylene 4,4′-diphenyl diisocyanate, 1,3-bis-(4,4′-isocyanto methyl) cyclohexane, and cyclohexane diisocyanate.

4. The copolymer of claim 1 , wherein each Diol is independently selected from the group consisting of an alkyl diol, a cycloalkyl diol, an alkyl cycloalkyl diol, an aryl diol or an alkylaryl diol having 1 to 10 carbon atoms and which may contain ether, thio or amine linkages in the main chain.

5. The copolymer of claim 4 , wherein each Diol is independently selected from the group consisting of 2,2-(4,4′-dihydroxydiphenyl)propane (bisphenol-A), 4,4′-iso-propylidine dicyclohexanol, ethoxylated and propoxylated bisphenol-A, 2,2-(4,4′-dihydroxydiphenyl)pentane, 1,1′-(4,4′-dihydroxydiphenyl)-p-diisopropyl benzene, 1,3-cyclohexane diol, 1,4-cyclohexane diol, 1-4-cyclohexane dimethanol, neopentyl glycol, 1,4-butanediol, 1,3-propanediol, 1,5-pentanediol, ethylene glycol, diethylene glycol and triethylene glycol.

6. The copolymer of claim 1 , wherein each PS is independently a diradical residue of a polysiloxane represented by the formula:

wherein:

each A is a hydroxyl or an amino radical;

each R is independently selected from an alkylene group having 1 to 10 carbon atoms wherein the carbon atoms may include ether, urethane or ureido linkages therebetween;

each R′ is independently selected from hydrogen, monovalent hydrocarbon radicals or halogen substituted monovalent hydrocarbon radicals wherein the hydrocarbon radicals have 1 to 20 carbon atoms which may include ether linkages therebetween, and

a is at least 1.

7. The copolymer of claim 6 , wherein each R is alkylene, and each R′ is independently alkyl or fluoroalkyl optionally including ether linkages.

8. The copolymer of claim 6 , wherein Mn of PS ranges from 1000 to 8000.

9. The copolymer of claim 1 , wherein the ratio of x to y is at least 0.6.

10. The copolymer of claim 1 , wherein each M is independently a polymerizable ethylenically unsaturated radical of the formula:

wherein:

R 23 is hydrogen or methyl;

each R 24 is hydrogen, an alkyl radical having 1 to 6 carbon atoms, or a —CO—Y—R 26 radical wherein Y is —O—, —S— or —NH—;

R 25 is a divalent alkylene radical having 1 to 10 carbon atoms;

R 26 is a alkyl radical having 1 to 12 carbon atoms;

Q is —CO—, —OCO— or —COO—;

X is —O— or —NH—;

Ar is an aromatic radical having 6 to 30 carbon atoms;

b is 0 to 6; c is 0 or 1; d is 0 or 1; and e is 0 or 1.

11. The copolymer of claim 1 , wherein:

each M is methacryloxyethyl;

each Dii is the diradical residue of isophorone diisocyanate;

each Diol is the diradical residue of diethyleneglycol;

each PS is a diradical residue of a polydimethylsiloxane-diol having Mn of at least 2000; and

each * is —NH—COO— or —OCO—NH—.

12. The copolymer of claim 1 , wherein the hydrophilic monomer selected form the group consisting of: ethylenically unsaturated carboxylic acids; (meth)acrylic substituted alcohols; vinyl lactams; and (meth)acrylamides.

13. The copolymer of claim 12 , wherein the hydrophilic monomer selected form the group consisting of: methacrylic acid; acrylic acid; 2-hydroxyethylmethacrylate; glyceryl methacrylate; N-vinyl pyrrolidone; methacrylamide; and N,N-dimethylacrylamide.

14. The copolymer of claim 1 , wherein the monofunctional silicone-containing monomer is methacryloxypropyl tris(trimethylsiloxy)silane.

15. A hydrogel copolymer that is the hydrated polymerization product of a monomeric mixture comprising a copolymer represented by the general formulae,

M(*Dii*Diol*Dii*PS) x (*Dii*PS) y *Dii*M or

M(*Dii*Diol*Dii*PS) x (*Dii*PS) y *Dii*Diol*Dii*M

wherein;

each M is independently a polymerizable ethylenically unsaturated radical;

each Dii is independently a diradical residue of a diisocyanate;

each Diol is independently a diradical residue of a diol having 1 to 10 carbon atoms;

each PS is independently a diradical residue of a polysiloxane-diol or a polysiloxane diamine;

each * is independently —NH—CO—NH—, —NH—COO— or —OCO—NH—;

x is at least 2, and

y is at least 1; and

a hydrophilic comonomer and a monofunctional silicone-containing monomer.

16. The hydrogel copolymer of claim 15 , having a water content of at least 20 weight percent.

17. The hydrogel copolymer of claim 15 , having a modulus no greater than 100 g/mm 2 .

18. The hydrogel copolymer of claim 17 , having a modulus between about 40 and 80 g/mm 2 .

19. The hydrogel copolymer of claim 15 , having an oxygen permeability of at least 100 barrers.

20. The hydrogel copolymer of claim 19 , having an oxygen permeability of at least 150 barrers.

21. The hydrogel copolymer of claim 15 , having a water content of at least 20 weight percent, a modulus between about 40 and 80 g/mm 2 , and an oxygen permeability of at least 150 barrers.

22. A biomedical device comprising a copolymer of claim 15 .

23. An ophthalmic device comprising a copolymer of claim 15 .

24. The ophthalmic device of claim 23 , that is a contact lens or an intraocular lens.

Assignments (9)
RELEASE OF SECURITY INTEREST Recorded Apr 8, 2025
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: SOLTA MEDICAL, INC.; PRECISION DERMATOLOGY, INC.; BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED); SALIX PHARMACEUTICALS, INC.; SALIX PHARMACEUTICALS, LTD; SANTARUS, INC.; MEDICIS PHARMACEUTICAL CORPORATION; HUMAX PHARMACEUTICAL S.A.; SOLTA MEDICAL IRELAND LIMITED; BAUSCH & LOMB MEXICO, S.A. DE C.V.; BAUSCH+LOMB OPS B.V.; BAUSCH HEALTH AMERICAS, INC.; BAUSCH HEALTH COMPANIES INC.; BAUSCH HEALTH HOLDCO LIMITED; BAUSCH HEALTH MAGYARORSZAG KFT (A/K/A BAUSCH HEALTH HUNGARY LLC); BAUSCH HEALTH POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (F/K/A VALEANT PHARMA POLAND SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA); BAUSCH HEALTH US, LLC; BAUSCH HEALTH, CANADA INC. / SANTE BAUSCH, CANADA INC.; ICN POLFA RZESZOW SPOLKA AKCYJNA (A/K/A ICN POLFA RZESZOW S.A.); ORAPHARMA, INC.; PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA SPOLKA AKCYJNA (A/K/A PRZEDSIEBIORSTWO FARMACEUTYCZNE JELFA S.A.); SOLTA MEDICAL DUTCH HOLDINGS B.V.; V-BAC HOLDING CORP.; VRX HOLDCO LLC; 1261229 B.C. LTD.; 1530065 B.C. LTD.
Reel/Frame 070778/0199 →
NOTICE OF SUCCESSION OF AGENCY Recorded Jan 9, 2015
From: GOLDMAN SACHS LENDING PARTNERS, LLC
To: BARCLAYS BANK PLC, AS SUCCESSOR AGENT
Reel/Frame 034749/0689 →
SECURITY AGREEMENT Recorded Sep 4, 2013
From: BAUSCH & LOMB INCORPORATED
To: GOLDMAN SACHS LENDING PARTNERS LLC, AS COLLATERAL AGENT
Reel/Frame 031156/0508 →
RELEASE OF SECURITY INTEREST Recorded Aug 13, 2013
From: CITIBANK N.A., AS ADMINISTRATIVE AGENT
To: WP PRISM INC. (N/K/A BAUSCH & LOMB HOLDINGS INC.); BAUSCH & LOMB INCORPORATED; ISTA PHARMACEUTICALS
Reel/Frame 030995/0444 →
SECURITY AGREEMENT Recorded Aug 6, 2012
From: BAUSCH & LOMB INCORPORATED; EYEONICS, INC.
To: CITIBANK N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 028728/0645 →
RELEASE OF SECURITY INTEREST Recorded Aug 5, 2012
From: CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 028726/0142 →
SECURITY AGREEMENT Recorded Nov 18, 2008
From: BAUSCH & LOMB INCORPORATED; WP PRISM, INC.; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; IOLAB CORPORATION; RHC HOLDINGS, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC; EYEONICS, INC.
To: CREDIT SUISSE
Reel/Frame 021849/0244 →
SECURITY AGREEMENT Recorded Nov 16, 2007
From: BAUSCH & LOMB INCORPORATED; B&L CRL INC.; B&L CRL PARTNERS L.P.; B & L DOMESTIC HOLDINGS CORP.; B&L FINANCIAL HOLDINGS CORP.; B&L SPAF INC.; B&L VPLEX HOLDINGS, INC.; BAUSCH & LOMB CHINA, INC.; BAUSCH & LOMB INTERNATIONAL INC.; BAUSCH & LOMB TECHNOLOGY CORPORATION; BAUSCH & LOMB REALTY CORPORATION; BAUSCH & LOMB SOUTH ASIA, INC.; SIGHT SAVERS, INC.; WILMINGTON MANAGEMENT CORP.; WILMINGTON PARTNERS L.P.; B&L MINORITY DUTCH HOLDINGS LLC; IOLAB CORPORATION; RHC HOLDINGS, INC.; WP PRISM, INC.
To: CREDIT SUISSE
Reel/Frame 020122/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 2, 2005
From: LAI, YU-CHIN; LANG, WEIHONG; QUINN, EDMOND T.
To: BAUSCH & LOMB INCORPORATED
Reel/Frame 017327/0436 →